Abstract
Background
Development of a positronemitting form of technetium has allowed the imaging of technetium radiopharmaceuticals with positron emission tomography (PET). We used94mTc to compare the distribution of the myocardial perfusion agent sestamibi at rest with the conventional PET perfusion tracer13N-labeled ammonia (13N-ammonia).
Methods and Results
Dosimetry calculations were performed with the known wholebody distribution of99mTc-labeled sestamibi. Dynamic PET imaging of13N-ammonia and94mTc-labeled sestamibi (94mTc-sestamibi) for 32 minutes was performed in eight patients with previous myocardial infarction. Initial myocardial and extramyocardial distribution of94mTc-sestamibi was compared with that of13N-ammonia by qualitative and quantitative analysis. Quantitative comparison of the two tracers was performed with region-of-interest analysis and circumferential profiles. Qualitatively, the cardiac distribution of the tracers was similar in normal and infarcted myocardium. A decrease in the definition of the epicardial and endocardial borders of the heart was seen with94mTc-sestamibi, presumably because of the lower dose of radionuclide injected. Quantitatively, there was no difference in infarct size, defined prospectively as tracer activity less than 20% of maximum activity for the section, between the two tracers. Circumferential profile analysis with 12-degree radial sections similarly demonstrated no difference in regional cardiac distribution of the tracers.
Conclusions
These results revealed no significant difference in myocardial uptake compared with13N-ammonia suggesting that the myocardial uptake of sestamibi correlates with that of myocardial perfusion.
Similar content being viewed by others
References
Nickles RJ, Nunn AD, Stone CK, Christian BT. Technetium-94m-teboroxime: synthesis, dosimetry and initial PET imaging studies. J Nucl Med 1993; 34: 1058–66.
Coleman PS, Metherall JA, Cao Q, et al. Comparison of rest-redistribution thallium-201 uptake with resting sestamibi uptake in coronary artery disease. J Nucl Med 1992; 33: 905.
Baudhuin T, Coppens A, Bol A, et al. Correlation of defect size and severity between Tc-99m sestamibi SPECT and N-13 ammonia PET imaging. J Nucl Med 1992; 33: 875.
Nickles RJ, Martin CC, Christian BT, Stone CK. Flow-through trapping to soften N-13 ammonia logistics. J Nucl Med 1992; 33: 931.
Finn R, Boothe T, Sinnreich J, Tavano E, Gilson A, Wolf AP. Ancillary cyclotron production of technetium-95m for clinical and chemical research. Radiopharmaceuticals and Labelled Compounds, IAEA-CN-45/22, Vienna, 1985.
Wackers FJT, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30: 301–11.
Snyder WS, Ford MR, Warner GG, Watson SB. “S” absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD pamphlet no. 11. New York: Society of Nuclear Medicine, 1975.
Stabin M, Watson E, Stabin M, Stubbs J. Letter to the editor. J Nucl Med 1994; 35: 923–4.
Sinusas AJ, Watson DD, Cannon JM Jr, Beller GA. Effect of ischemia and postischemic dysfunction on myocardial uptake of technetium-99m-labeled methoxyisobutyl isonitrile and thallium-201. J Am Coll Cardiol 1989; 14: 1785–93.
Kahn J, McGhie I, Akers M, et al. Quantitative rotational tomography with201Tl and99mTc-2-methoxyisobutyl isonitrile: a direct comparison in normal individuals and patients with coronary artery disease. Circulation 1989; 79: 1282–93.
Gibbons R, Verani M, Behrenbeck T, et al. Feasibility of tomographic Tc-99m-hexakis-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 1989; 80: 1277–86.
Duda GD, Handler P. Kinetics of ammonia metabolismin vivo. J Biol Chem 1958; 232: 303–14.
Shah A, Schelbert HR, Schwaiger M, Hansen H, Selin C. Measurement of regional myocardial blood flow with N-13 ammonia and positron-emission tomography in intact dogs. J Am Coll Cardiol 1985; 5: 92–100.
Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990; 15: 1032–42.
Bol A, Melin JA, Vanoverschelde JL, et al. Direct comparison of [13N]ammonia and [15O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation 1993; 87: 512–25.
Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884–8.
Bergmann SR, Hack S, Tewson T, Welch MJ, Sobel BE. The dependence of accumulation of13NH3 by myocardium on metabolic factors and its implications for quantitative assessment of perfusion. Circulation 1980; 61: 34–43.
Delbeke D, Lorenz CH, Votaw JR, et al. Estimation of left ventricular mass and infarct size from nitrogen-13-ammonia PET images based on pathological examination of explanted human hearts. J Nucl Med 1993; 34: 826–33.
Piwnica-Worms D, Kronauge J, Chiu M. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in culture chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826–38.
Leppo JA, Meerdink DJ. Comparison of the myocardial uptake of a technetium-labeled isonitrile analogue and thallium. Circ Res 1989; 65: 632–9.
Leppo JA, Meerdink DJ. Comparative myocardial extraction of two technetium-labeled boron oxime derivatives (SQ30217, SQ32014) and thallium. J Nucl Med 1990; 31: 67–74.
Garcia EV, Cooke CD, Van Train KF, et al. Technical aspects of myocardial SPECT imaging with technetium 99m sestamibi. Am J Cardiol 1990; 66: 22E-31E.
Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation 1988; 77: 491–8.
Verani M, Jeroudi M, Mahmarian J, et al. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrile. J Am Coll Cardiol 1988; 12: 1573–81.
Melin JA, DeKock M, Decoster P, Dereme T, Wijns W. Comparative assessment of myocardial vability with thallium-201 and Tc-99m sestamibi SPECT imaging. J Nucl Med 1992; 33: 905.
Sawada SG, Allman KC, Muzik O, et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 1994; 1: 92–8.
Stone CK, Christian BT, Nickles RJ, Pyzalski RW, Perlman SB. Study of myocardial distribution of94mTc-sestamibi with positron emission tomography: comparison to resting13N-ammonia. J Am Coll Cardiol 1993; 21: 461A.
Baudhuin T, Coppens A, Bol A, et al. Discrepancies in perfusion defect estimates between Tc-99m MIBI SPECT and N-13 ammonia PET are not explained by differences in tracer behavior. J Nucl Med 1993;34:121P.
Christian BT, Nickles RJ, Stone CK. Producing Tc-94m from isotopically enriched [Mo-94]MoO3. J Nucl Med 1993;34:248P.
Nickles RJ, Christian BT, Mulnix TL, Stone CK. Quantitating technetium pharmacokinetics with PET, SPECT, and beta spectroscopy. Presented at the Tenth International Symposium on Radiopharmaceutical Chemicals, Kyoto, Japan, Oct. 25–28, 1993.
Author information
Authors and Affiliations
Additional information
Supported by National Institutes of Health grant R29 HL47003 (FIRST Award). Presented in part at the Forty-second Annual Scientific Sessions of the American College of Cardiology, March 1993.
Rights and permissions
About this article
Cite this article
Stone, C.K., Christian, B.T., Nickles, R.J. et al. Technetium 94m-labeled methoxyisobutyl isonitrile: Dosimetry and resting cardiac imaging with positron emission tomography. J. Nucl. Cardiol. 1, 425–433 (1994). https://doi.org/10.1007/BF02961596
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02961596